1. All Products
  2. VACCINE MENINGOCOCCAL A CONJ. 3-24months, 1dose, multid.vial
Public Pricelist

VACCINE MENINGOCOCCAL A CONJ. 3-24months, 1dose, multid.vial

https://medicalguidelines.msf.org/en/node/966
https://unicat.msf.org/cat/product/53884
STD DVACVMENA2VD

Valid Article

Former Code(s): DVACVMENA2V DVACZNL0045
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
Article is intended to be used with children (<12 years) ONLY.
19.3 - Vaccines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J07AH10
Anatomical Therapeutic Chemical Classification according to WHOCC
P
The order of this product needs to be justified and is only acceptable under certain conditions.
0208
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

VACCINE MENINGITIS A CONJUGATE 3-24 months

CAUTION

This multidose vaccine is worded and codified by unit (= 1 dose) to make the order.

Full Name

MenAfriVac 5µg®

Therapeutic Action

Freeze-dried vaccine inducing the production of bactericidal antibodies specific to the capsular polysaccharides of Neisseria meningitidisserogroup A.

Indications

Routine immunisation against meningitis due to Neisseria meningitidis group A in children from 3 to 24 months of age.

In mass immunisation campaigns targeting children over one year of age, it is recommended to use a conjugate vaccine, preferably the meningococcal ACYWX vaccine (MenFive®) as first choice.

The countries that have already introduced a monovalent meningococcal A conjugate vaccine into their routine programme should progressively switch to MenFive® vaccine.

The vaccine needs to be registered in the country.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Reconstitute the powder vial with the diluent supplied by the manufacturer.

1 dose = 0.5 ml reconstituted suspension = 5 µg meningococcal polysaccharide

Must be given as IM injection into the anterolateral part of the thigh in children < 2 years or into the deltoid muscle in children ≥ 2 years.

According the schedule recommended in the country:

  • children aged 3-9 months: 2 doses at least 8 weeks apart
  • children aged 9-24 months: 1 single dose

Do not forget to order the diluent (3-24 m) together with the vaccine!

Orders are always done in number of doses and not in number of vials! (See Preliminary remarks on Vaccines)

Precautions for Use

As with all injectable vaccines and/or immunoglobulins, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the product.

Storage

  • Do not freeze.
  • Powder: between 2ºC and 8°C - Protect from sunlight
  • Diluent: cold chain is not required for storage. However, at least 12 hrs before reconstitution of the vaccine, the diluent must be refrigerated between 2ºC and 8ºC so that the diluent and lyophilised powder are at the same temperature (a thermic shock during reconstitution could reduce the vaccine efficacy).
  • Vaccine reconstituted: between 2°C and 8°C for 6 hrs maximum, protected from the light
  • MenAfriVac 5µg®vaccine is not pre-qualified for CTC (Controlled Temperature Chain).
  • The vaccine vial monitor (VVM) is mandatory on each vaccine.

(Cf Introduction: Thermosensitive products)